Currently Viewing:
Newsroom
Currently Reading
Unmet Care Targets Suggest Need for Improved Diabetes Care Accessibility
August 18, 2019 – Alison Rodriguez
Blood Clots in MPN Related to Higher Cost, Length of Stay for Patients With MPN
August 17, 2019 – AJMC Staff
Researchers Seek to Determine Genetic Variability in Parkinson Progression
August 17, 2019 – AJMC Staff
FDA Panel Backs Use of Descovy for HIV Prevention in Men, Transgender Women
August 16, 2019 – Jaime Rosenberg
Researcher Excited About Future of Psoriasis Treatment
August 16, 2019 – Allison Inserro
This Week in Managed Care: August 16, 2019
August 16, 2019
AJMC® in the Press, August 16, 2019
August 16, 2019 – AJMC Staff
Pediatric Leukemia Treatment Linked to Increased Risk of Infections, Study Finds
August 16, 2019 – Alison Rodriguez
5 Findings From the August 2019 Issue of AJMC®
August 16, 2019 – Christina Mattina

HIV, Hepatitis C Drugs Continue to Be Most Costly Group of Outpatient Drugs for Medicaid

Jaime Rosenberg
Between 2014 and 2017, antivirals were consistently the number 1 most costly outpatient drug group for Medicaid, and HIV antiretrovirals and hepatitis C drugs accounted for more than 90% of spending on these antivirals.
Between 2014 and 2017, antiviral medications that treat HIV and hepatitis C cost the Medicaid program more than did any other group of outpatient prescription drugs, according to an analysis from the Kaiser Family Foundation.

During the 4-year period, spending on outpatient prescription drugs increased from $45.9 billion to $63.6 billion, as drug utilization increased from 621.7 million prescriptions to 752.9 million. In 2017 alone, antivirals accounted for more than 13% of the $63.6 billion spent on Medicaid outpatient drugs, which the authors of the report said is due to their high list price and not due to utilization.

“Because states must balance their budgets, ongoing increased spending on Medicaid prescription drugs is a policy concern, prompting states to consider ways to reduce drug spending,” wrote the researchers. “Understanding patterns and trends in drug spending is crucial to effectively managing the benefit and developing strategies to address high drug costs.”

While the Medicaid pharmacy benefit includes more than 90 classes of drugs, the 10 most costly and utilized classes consistently account for a disproportionate percentage, accounting for nearly half of all prescriptions and about two-thirds of spending. During the period, both utilization and spending increased more rapidly between 2014 and 2015, reflecting implementation of Medicaid expansion and a jump in the number of beneficiaries. Spending on Medicaid outpatient drugs is expected to continue to grow as a faster pace than other Medicaid services in the next 10 years, due in large part to the launch of high-cost drugs, as well as the increase in Medicaid beneficiaries.

Throughout the study period, antivirals were consistently the number 1 most costly drug group, and HIV antiretrovirals and hepatitis C drugs accounted for more than 90% of spending on these antivirals. The researchers note that Medicaid is the largest source of coverage for individuals with HIV, providing coverage for more than 40% of those with the virus. However, despite being among the top 10 costliest drugs, antivirals were not among the top 10 most utilized drugs during any of the years analyzed.

The drugs most utilized included narcotic and nonnarcotic painkillers, antidepressants, anticonvulsants, ulcer drugs, antidiabetic drugs, and antihypertensives. During the 4-year period, the same groups made up the top 10 most prescribed drugs each year. However, in recent years, antidepressants have become the most prescribed drug class, accounting for approximately 7% of total prescriptions in 2017.

“Medicaid expansion at least in part explains the increased use of antidepressants, as behavioral health needs, with depression and anxiety in particular, were common amongst the expansion population, and the Affordable Care Act requires that Medicaid provide behavioral health treatment,” explained the researchers.

Notably, the spending on antidiabetics increased by 42% during the study period, with spending nearly doubling. In 2014, antidiabetics were the fifth most costly class of drugs, and by 2017, they were the second most costly class.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up